Ciclosporin Ophthalmic (Optimmune)

Ciclosporin, also spelled cyclosporine in some regions, is a powerful immunomodulatory medication that has become an important tool in equine ophthalmology for managing immune-mediated ocular conditions. Originally developed as a systemic immunosuppressant for organ transplantation, the ophthalmic formulation allows targeted delivery to the eye while minimizing systemic exposure. In horses, topical ciclosporin has proven particularly valuable for treating chronic inflammatory conditions of the cornea and ocular surface that do not respond adequately to conventional anti-inflammatory therapy.

The mechanism of action of ciclosporin involves inhibition of calcineurin, a critical enzyme in T-lymphocyte activation. By blocking this pathway, ciclosporin suppresses the production of inflammatory cytokines, particularly interleukin-2, that drive immune-mediated tissue damage in the eye. This targeted immunomodulation allows the medication to reduce pathological inflammation while preserving essential immune functions. Additionally, ciclosporin has been shown to have lacrimogenic properties, meaning it can help increase tear production, which provides additional benefit for horses with concurrent dry eye conditions.

Optimmune, the most commonly used commercial preparation, is formulated as a 0.2% ciclosporin ophthalmic ointment in a corn oil base. While this product is specifically labeled for use in dogs with keratoconjunctivitis sicca, veterinary ophthalmologists frequently prescribe it off-label for equine patients with appropriate indications. Compounded ciclosporin preparations in various concentrations and vehicles are also available for horses, allowing veterinarians to customize treatment for individual patients. The ointment formulation provides extended contact time with the ocular surface compared to aqueous drops.

The safety profile of topical ciclosporin in horses is generally excellent when used as directed, though the medication requires consistent long-term administration for many conditions. Because ciclosporin works by modulating the immune response rather than simply suppressing inflammation, clinical improvement typically develops gradually over several weeks to months of treatment. Veterinary supervision is essential to ensure proper diagnosis, appropriate patient selection, and monitoring of treatment response over time.

The primary indication for ciclosporin ophthalmic therapy in horses is immune-mediated keratitis, a group of conditions characterized by chronic corneal inflammation driven by abnormal immune responses. These conditions often present as persistent corneal opacity, neovascularization, and discomfort that does not resolve with standard anti-inflammatory treatment. Immune-mediated keratitis in horses can result from various underlying causes, including chronic herpesvirus infection, allergic or atopic conditions, and idiopathic autoimmune processes. Ciclosporin's ability to modulate the aberrant immune response makes it particularly effective for these challenging cases.

Eosinophilic keratitis is a specific type of immune-mediated corneal disease that responds particularly well to ciclosporin therapy. This condition is characterized by the presence of eosinophils, mast cells, and plasmacytes within the corneal stroma, often creating a distinctive white or pink plaque-like appearance on the corneal surface. While the exact cause of eosinophilic keratitis in horses is not fully understood, it appears to represent a hypersensitivity reaction that requires immunomodulatory treatment. Ciclosporin helps resolve the active inflammation and can be used long-term to prevent recurrence in susceptible individuals.

Chronic superficial keratitis, sometimes called pannus in other species, involves progressive inflammatory infiltration and vascularization of the corneal surface. While this condition is less common in horses than in certain dog breeds, equine patients with similar corneal changes benefit from ciclosporin therapy. The medication helps reduce ongoing inflammation, limit further vascular invasion of the cornea, and in some cases allows partial regression of established changes. Early intervention with ciclosporin typically yields better outcomes than treatment of advanced disease.

Equine recurrent uveitis, also known as moon blindness, may benefit from ciclosporin as an adjunctive therapy, though it is not a first-line treatment for acute episodes. For horses with chronic low-grade uveitis or those in the inter-episode period, topical ciclosporin can help modulate the immune response that drives recurrent inflammation. This application is most appropriate for cases where traditional corticosteroid therapy is insufficient or contraindicated, and it is typically used in combination with other management strategies rather than as sole therapy.

Secondary benefits of ciclosporin therapy include improvement in tear film quality and quantity for horses with concurrent keratoconjunctivitis sicca or qualitative tear film abnormalities. The lacrimogenic effect of ciclosporin helps restore a healthy ocular surface environment, which supports healing and helps prevent secondary complications. This property makes ciclosporin particularly valuable for horses with multiple concurrent ocular surface problems.

The dosing of ciclosporin ophthalmic preparations in horses requires careful veterinary guidance, as the medication is typically used off-label and protocols may be customized based on the specific condition and individual patient response. Your veterinarian will determine the appropriate formulation, concentration, and dosing frequency based on a thorough ophthalmic examination and diagnosis. Because immune-mediated conditions often require long-term management, the initial treatment plan should include provisions for follow-up evaluation and protocol adjustment as needed.

Typical dosing with Optimmune ointment or equivalent 0.2% preparations involves application of a small ribbon of ointment, approximately one-quarter to one-half inch in length, to the affected eye. Initial therapy usually begins with twice-daily application, which may be adjusted to once daily for maintenance therapy once the condition is well-controlled. Some horses with severe or refractory disease may require more frequent application during the initial treatment phase, as directed by your veterinarian. Higher concentration compounded preparations may require different dosing schedules.

Treatment duration with ciclosporin is typically measured in weeks to months, and many horses require long-term or even lifelong therapy to maintain control of immune-mediated conditions. Clinical improvement generally begins within two to four weeks of initiating treatment, though maximal benefit may not be apparent for two to three months. Your veterinarian will schedule periodic reexaminations to assess response and determine whether the treatment protocol should be modified. Premature discontinuation commonly results in recurrence of clinical signs.

Proper administration technique for ciclosporin ointment involves gently pulling down the lower eyelid to create a small pocket and depositing the ointment ribbon inside this space. The medication will spread across the corneal surface with normal blinking. For horses that are difficult to treat, your veterinarian may demonstrate modified techniques or recommend mild sedation for initial treatments until the horse becomes accustomed to the procedure. Consistent, gentle handling helps establish a routine that makes long-term treatment manageable.

If a dose is missed, it should be administered as soon as possible, then the regular schedule resumed. For twice-daily dosing, a single missed dose is unlikely to significantly impact disease control, but consistent administration is important for maintaining therapeutic benefit. Do not attempt to apply double amounts to compensate for missed doses. If multiple consecutive doses are missed, contact your veterinarian for guidance on resuming therapy, as some conditions may flare with treatment interruption.

The importance of completing the prescribed treatment course cannot be overemphasized with ciclosporin therapy. Unlike antibiotics where a defined course treats an infection, ciclosporin is typically prescribed for chronic conditions that require ongoing management. Stopping treatment when the eye looks better almost invariably results in recurrence of inflammation, often within weeks. Your veterinarian will guide decisions about whether and when treatment might be safely discontinued or reduced to a maintenance schedule.

Topical ciclosporin is generally well-tolerated in horses, with most patients experiencing no significant adverse effects during treatment. The ointment formulation may cause transient blurring of vision immediately after application due to the oil base, but this typically resolves within fifteen to thirty minutes as the medication disperses across the ocular surface. This temporary effect is a property of the vehicle rather than the active ingredient and does not indicate any harm to the eye.

Mild local irritation is the most commonly reported side effect of ciclosporin ophthalmic therapy. This may manifest as brief increased blinking, mild redness of the conjunctiva, or slight increase in tearing immediately after application. These reactions usually diminish with continued use as the eye adapts to the medication, and they rarely necessitate discontinuation of therapy. If local irritation persists or worsens, this should be reported to your veterinarian, as it may indicate sensitivity to the vehicle or need for formulation change.

Some horses may develop a superficial ocular discharge during ciclosporin therapy, particularly with ointment formulations. This mucoid discharge represents accumulated medication residue mixed with normal ocular secretions rather than an adverse reaction. Gentle cleaning of discharge from the medial canthus as needed helps maintain patient comfort. If discharge becomes purulent or is accompanied by increased pain or redness, veterinary evaluation is warranted to rule out secondary bacterial infection.

Serious side effects from topical ciclosporin are rare in horses. Because systemic absorption from topical application is minimal, the significant toxicities associated with systemic ciclosporin therapy, such as nephrotoxicity and immunosuppression, are not concerns with ophthalmic use. However, in rare cases, local immunosuppression may theoretically increase susceptibility to ocular infections. For this reason, ciclosporin should be used with caution in eyes with active infection and should be discontinued if new infection develops during therapy.

Long-term use of ciclosporin has not been associated with significant cumulative toxicity to the equine eye, and many horses receive this medication for years without adverse effects. Periodic veterinary monitoring remains important during extended therapy to assess both treatment efficacy and ocular health. Any new symptoms or changes in the appearance of the treated eye should prompt veterinary evaluation, as these may represent progression of the underlying condition rather than medication side effects.

The primary contraindication to ciclosporin ophthalmic therapy is the presence of active ocular infection. Ciclosporin's immunomodulatory mechanism can impair local immune defenses, potentially allowing infectious organisms to proliferate unchecked. This concern is particularly relevant for fungal infections, which can be challenging to diagnose and treat in horses and may worsen significantly under immunosuppressive conditions. Before initiating ciclosporin therapy, your veterinarian will carefully evaluate the eye to rule out infectious causes of inflammation.

Corneal ulceration is generally considered a contraindication to ciclosporin use until the ulcer has healed. While ciclosporin does not directly impair wound healing to the same extent as corticosteroids, the immunomodulatory effect can reduce the eye's ability to fight infection, which is a significant risk when the corneal barrier is compromised. Some veterinary ophthalmologists may use ciclosporin in the later stages of ulcer healing for specific conditions, but this decision requires expert judgment and close monitoring.

Known hypersensitivity to ciclosporin or any component of the ophthalmic formulation represents an absolute contraindication. True allergic reactions to ciclosporin are rare, but horses that have shown significant adverse reactions to previous ciclosporin use should not receive the medication again. Sensitivity to the vehicle components, particularly corn oil in commercial preparations, is also possible and may necessitate use of alternative formulations rather than complete avoidance of the drug.

Purulent ocular discharge or other signs suggesting bacterial infection require treatment of the infection before or concurrent with ciclosporin therapy. In some cases, veterinarians may initiate antibiotic treatment alongside ciclosporin for mixed conditions involving both immune-mediated inflammation and secondary bacterial involvement. However, primary bacterial keratitis or conjunctivitis should be resolved before relying on ciclosporin for ongoing management.

Ciclosporin ophthalmic therapy is compatible with most other topical eye medications commonly used in equine practice, and combination therapy is frequently employed for complex ocular conditions. However, attention to proper timing of medication administration and awareness of potential interactions helps optimize therapeutic outcomes. Your veterinarian will design a comprehensive treatment protocol that addresses all aspects of your horse's ocular condition while avoiding problematic interactions.

Topical corticosteroids are sometimes used in combination with ciclosporin for horses with severe immune-mediated inflammation, as the two drug classes work through complementary mechanisms. While both medications suppress inflammation, ciclosporin targets specific immune pathways while corticosteroids have broader anti-inflammatory effects. This combination may allow lower doses of each medication to be used while achieving better disease control. However, both drugs can reduce local immune function, so careful monitoring for secondary infection is essential when using this combination.

Antibiotic eye medications can be safely used with ciclosporin when indicated, with appropriate spacing between applications to allow each medication adequate contact time with the ocular surface. A minimum interval of five to ten minutes between different eye medications is generally recommended. The oil base of ciclosporin ointment may affect absorption of water-based drops applied immediately afterward, so your veterinarian may provide specific guidance on administration sequence.

Atropine, used for pupil dilation and pain control in horses with uveitis, is compatible with ciclosporin therapy. Many horses with immune-mediated ocular disease receive both medications as part of comprehensive management. There is no pharmacological interaction between these drugs, and they can be applied in the same treatment session with appropriate spacing. Non-steroidal anti-inflammatory drops are also compatible with ciclosporin and may be used together for conditions requiring multiple approaches to inflammation control.

Monitoring requirements during ciclosporin therapy include periodic veterinary eye examinations to assess treatment response and detect any complications. The frequency of monitoring visits depends on the severity and stability of the condition, typically ranging from every two to four weeks during initial therapy to every three to six months once the condition is well-controlled. These examinations may include fluorescein staining to check for corneal defects, intraocular pressure measurement, and detailed evaluation of corneal clarity and inflammation.

Foals and young horses may receive ciclosporin therapy when indicated, though experience in very young equine patients is more limited than in adults. The developing immune system in young horses may respond differently to immunomodulatory therapy, and some veterinarians prefer to delay ciclosporin use until horses are older unless the condition is severe. Your veterinarian will weigh the benefits of treatment against any theoretical concerns based on your foal's specific situation and the severity of the ocular disease.

Competition and performance horses can generally continue ciclosporin therapy during training and competition, as this medication is not typically considered a prohibited substance under most equine competition rules. However, competition rules vary by organization and may change, so verification with the relevant regulatory body is recommended before competing. More importantly, horses receiving treatment for active ocular inflammation should have their fitness for competition evaluated by a veterinarian, as compromised vision can create safety concerns regardless of medication status.

Safe handling of ciclosporin ophthalmic ointment includes avoiding contact with the medication and washing hands thoroughly after administration. While topical exposure poses minimal risk to healthy individuals, ciclosporin is a potent immunosuppressant, and routine precautions are appropriate. Pregnant women or individuals with compromised immune systems should use gloves when applying the medication or have another person administer it to the horse.

Long-term use considerations are particularly relevant for ciclosporin therapy, as many horses require years of treatment for chronic immune-mediated conditions. The medication has an excellent long-term safety profile when used topically, but the commitment to ongoing treatment should be understood at the outset. Periodic reassessment of the need for continued therapy is appropriate, though most horses with conditions responsive to ciclosporin will require some level of ongoing treatment to maintain control.

Proper storage of ciclosporin ophthalmic preparations ensures maintenance of potency and sterility throughout the product's shelf life. Optimmune and similar commercial preparations should be stored at controlled room temperature, typically between fifteen and thirty degrees Celsius (fifty-nine to eighty-six degrees Fahrenheit), protected from excessive heat and direct sunlight. Storage in a tack room is acceptable provided temperature extremes are avoided; bringing the medication indoors during very hot or cold weather helps maintain product quality.

Handling ciclosporin ointment requires attention to hygiene and contamination prevention. The tip of the tube should not contact any surface, including the eye, eyelids, or fingers, to prevent bacterial contamination of the remaining product. After each use, the cap should be replaced immediately and securely. If the tube tip becomes contaminated during application, wiping with a clean tissue before capping is acceptable, but heavily contaminated tubes should be discarded and replaced to prevent introducing bacteria into the eye.

Compounded ciclosporin preparations may have specific storage requirements that differ from commercial products, depending on the vehicle and preservatives used. Follow the specific instructions provided by the compounding pharmacy, which typically include refrigeration for preservative-free preparations. Compounded medications generally have shorter expiration dates than manufactured products, and this should be noted to ensure use within the appropriate timeframe. Never use ophthalmic medications beyond their expiration date, as reduced potency or contamination may result in treatment failure or harm.

Draft horses and other large breeds may require standard ciclosporin therapy for immune-mediated ocular conditions, with no specific dose adjustments required for topical ophthalmic use. The medication is applied directly to the eye, and the dose is independent of body weight. However, the larger eye size in draft breeds may warrant slightly longer ribbons of ointment to ensure adequate distribution across the corneal surface. As with all breeds, consistent twice-daily or once-daily application as prescribed is essential for therapeutic success.

Warmbloods and sport horses frequently receive ciclosporin therapy, as these breeds are commonly affected by various immune-mediated ocular conditions. The demands of athletic careers may complicate treatment compliance, particularly for horses traveling to competitions, but the medication's stability at room temperature facilitates transport. Owners should ensure continuity of treatment during travel and competition periods, and competition clearance should be verified with relevant regulatory authorities.

Ponies and miniature horses receive the same ciclosporin preparations as full-sized horses, with application technique adjusted for their smaller eye size. Proportionally smaller amounts of ointment are appropriate, though the difference is modest given that even large horse eyes require only small ribbon lengths. These smaller equines may be more sensitive to handling around the face, potentially requiring more gradual desensitization to treatment.

Appaloosas warrant special mention in any discussion of equine eye medications due to their dramatically increased incidence of equine recurrent uveitis. While ciclosporin is not the primary treatment for acute uveitis, Appaloosas with chronic immune-mediated ocular surface disease or those requiring adjunctive immunomodulation may benefit from this therapy. Given the high prevalence of ocular problems in this breed, owners should be particularly vigilant about monitoring eye health and maintaining consistent treatment protocols when prescribed.

Tacrolimus ophthalmic is a closely related immunomodulatory medication that shares ciclosporin's mechanism of action as a calcineurin inhibitor but with significantly higher potency. In equine patients who do not respond adequately to ciclosporin therapy, tacrolimus may be considered as an alternative. The two medications are not typically used simultaneously due to their overlapping mechanisms, but switching from ciclosporin to tacrolimus or vice versa may be appropriate for individual cases. Your veterinarian can advise whether tacrolimus might offer advantages for your horse's specific condition.

Topical corticosteroids represent an alternative class of anti-inflammatory medications that may be used instead of or in addition to ciclosporin for immune-mediated ocular disease. Prednisolone acetate, dexamethasone, and other corticosteroid preparations work through different mechanisms than ciclosporin and may be more appropriate for certain conditions or patients. However, corticosteroids carry greater risk of delaying corneal healing and predisposing to infection, making ciclosporin preferred for long-term management of many conditions.

Non-steroidal anti-inflammatory ophthalmic preparations, such as flurbiprofen or diclofenac, provide anti-inflammatory effects without the immunosuppressive properties of ciclosporin or corticosteroids. These medications may be useful adjuncts for horses with inflammatory conditions but are generally less effective than immunomodulatory agents for primarily immune-mediated disease. Your veterinarian may recommend NSAIDs as part of combination therapy or as alternatives when ciclosporin is contraindicated.